Spondyloarthritis & psoriatic arthritis

Understanding difficult-to-treat psoriatic arthritis: Data from the Rheumatic Diseases Portuguese Registry

Joint Bone SpinePublished Retrospective cohort study

Authors' conclusion

D2T PsA proportions varied between 0.9% and 3.7%. D2T PsA patients had higher disease activity scores before the initiation of their first b/tsDMARDs and higher rates of treatment discontinuation.

Study context

Population
Patients with psoriatic arthritis (PsA) registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt)
Participants
1,873 patients
Exposure
Difficult-to-treat (D2T) PsA vs non-D2T PsA
  • D2T PsA (first definition)n = 70
  • D2T PsA (second definition)n = 17
Outcome
Proportion of D2T PsA and its predictors
Methodological detailsmulticentre, observational, registry-based (Reuma.pt)
  • Multicentre
  • Observational
  • Registry-based (Reuma.pt)

Main finding

As reported in the abstract

Proportion classified as D2T PsA
Predictor of D2T PsA: polyarticular disease
OR: 3.09
Predictor of D2T PsA: increased baseline swollen joint count
OR: 1.12
Predictor of D2T PsA: treatment duration on the first b/tsDMARDs
P < 0.01

Observational data: associations, not effects.

Further findings

Characteristics associated with D2T PsA (D2T vs non-D2T) · baseline

Age at symptom onset
37.5±11.0 vs. 41.4±12.8; P<0.01
Age at diagnosis
40.7±10.5 vs. 44.7±12.3; P<0.01
Polyarticular phenotype
77.6% vs. 53.6%; P<0.001
Depression
10.9% vs. 5%; P<0.05
Enthesitis
47.1% vs. 33.5%; P<0.05
BMI (lower in D2T)
26.5[6.1] vs. 27.7[6.1]; P<0.01
Tender joint count
13.4[14.5] vs. 6[8]; P<0.001
Swollen joint count
9[9] vs. 4[6]; P<0.001
DAPSA
38.2[31.6] vs. 25.4[15.6]; P<0.001

Original publication

Understanding difficult-to-treat psoriatic arthritis: Data from the Rheumatic Diseases Portuguese Registry. Joint Bone Spine. Published 24 July 2025. doi:10.1016/j.jbspin.2025.105949

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.